<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884776</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACT Study</org_study_id>
    <nct_id>NCT04884776</nct_id>
  </id_info>
  <brief_title>Modulation of Gut Microbiota to Enhance Health and Immunity</brief_title>
  <official_title>Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The novel coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus is now a pandemic&#xD;
      and has culminated major morbidity and mortality globally. Studies have shown that patients&#xD;
      with underlying type 2 diabetes mellitus (DM), obesity, old age and hypertension had a higher&#xD;
      risk of developing severe COVID-19 infection and mortality related to COVID-19.Emerging&#xD;
      evidence has shown that gut microbiota plays an important role in the pathogenesis of&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESIS We hypothesize that modulating the gut microbiota with a microbiome immunity&#xD;
      formula can rebalance the gut microbiota in populations at risk of infection, like, patients&#xD;
      with type 2 DM and elderlies and can lower the number of hospitalisation and reduce side&#xD;
      effects associated with COVID-19 vaccination.&#xD;
&#xD;
      AIM We aim to evaluate the efficacy of modulating gut microbiota with a microbiome immunity&#xD;
      formula in vulnerable subjects (patients with underlying type 2 DM and elderlies) in&#xD;
      improving immune functions, reducing adverse events associated with COVID-19 vaccinations and&#xD;
      reducing hospitalisation in susceptible individuals during the COVID-19 pandemic.&#xD;
&#xD;
      STUDY DESIGN This is a double-blinded, randomized, active-placebo controlled study comparing&#xD;
      a microbiome immunity formula and placebo in enhancing immunity and reducing hospitalisation&#xD;
      within one year. Except two kinds of subjects (Substudy 1: Patients with Type 2 DM and&#xD;
      Substudy 2: Elderly individual) will be included in respective substudy, all other&#xD;
      methodologies are the same. In each substudy, at least half of the recruited subjects will&#xD;
      plan to receive COVID-19 vaccination and start to take the study products after vaccination.&#xD;
      Recruited subjects will be randomised to receive a microbiome immunity formula or active&#xD;
      placebo for 3 months, with another 9 months follow-up after completion of study products.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of gut dysbiosis</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients achieving restoration of gut dysbiosis at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of the COVID-19 vaccine</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Measured by serum neutralization assay against pseudo virus and live virus, and IgM and IgG against receptor-binding domain [RBD] and S1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiome</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>Measured the microbial analysis result by real time-PCR and metabolite profiling by liquid chromatography-mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma inflammatory cytokines</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Measured the inflammatory cytokines (CRP or ESR) in blood result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events after COVID-19 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unscheduled hospitalisation and clinic visits</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>Number of unscheduled hospitalisation and clinic visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of quality of life</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>Measured the score of EQ-5D-5L which measure the health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycaemic control</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Measured by HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">484</enrollment>
  <condition>Gut Microbiota</condition>
  <condition>COVID-19 Vaccine</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will be instructed to take microbiome immunity formula 2 sachets daily for a total of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be instructed to take active placebo daily for a total of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Microbiome immunity formula</intervention_name>
    <description>Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)</description>
    <arm_group_label>Active arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active placebo</intervention_name>
    <description>Active placebo contains active vitamin</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Substudy 1&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years - below 65 years&#xD;
&#xD;
          2. A confirmed diagnosis of type 2 DM for ≥ 3 months with stable control (i.e. no change&#xD;
             in DM medications in recent 2 months)&#xD;
&#xD;
          3. Written informed consents obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of confirmed COVID-19 infection&#xD;
&#xD;
          2. Known active sepsis or active malignancy&#xD;
&#xD;
          3. Known increased infection risk due to underlying immunosuppressed state which&#xD;
             includes:&#xD;
&#xD;
               -  Prior organ or hematopoietic stem cell transplant&#xD;
&#xD;
               -  Neutropenia with absolute neutrophil count (ANC) &lt;500 cells/ul at the time of&#xD;
                  study inclusion&#xD;
&#xD;
               -  Known HIV infection with CD4 &lt;200 cells/ul at the time of study inclusion&#xD;
&#xD;
               -  On concomitant immunosuppressants or corticosteroid at a dose of prednisolone&#xD;
                  equivalent dose 10mg or more for more than 3 months&#xD;
&#xD;
          4. Known history or active infective endocarditis&#xD;
&#xD;
          5. On peritoneal dialysis or haemodialysis&#xD;
&#xD;
          6. Documented pregnancy&#xD;
&#xD;
        Substudy 2&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 65 years and above&#xD;
&#xD;
          2. Written informed consents obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of confirmed COVID-19 infection&#xD;
&#xD;
          2. Known active sepsis or active malignancy&#xD;
&#xD;
          3. Known increased infection risk due to underlying immunosuppressed state which&#xD;
             includes:&#xD;
&#xD;
               -  Prior organ or hematopoietic stem cell transplant&#xD;
&#xD;
               -  Neutropenia with absolute neutrophil count (ANC) &lt;500 cells/ul at the time of&#xD;
                  study inclusion&#xD;
&#xD;
               -  Known HIV infection with CD4 &lt;200 cells/ul at the time of study inclusion&#xD;
&#xD;
               -  On concomitant immunosuppressants, chemotherapies or corticosteroid at a dose of&#xD;
                  prednisolone equivalent dose 10mg or more for more than 3 months&#xD;
&#xD;
          4. Known history or active infective endocarditis&#xD;
&#xD;
          5. On peritoneal dialysis or haemodialysis&#xD;
&#xD;
          6. Known active malignancy&#xD;
&#xD;
          7. Known terminal illness with life expectancy less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce WY Mak, FHKAM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce WY Mak, FHKAM</last_name>
    <phone>3505 3307</phone>
    <email>wingyanmak@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Li</last_name>
    <phone>26373225</phone>
    <email>amyli@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital, Shatin</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce WY Mak, FHKAM</last_name>
      <phone>3505 3307</phone>
      <email>wingyanmak@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, Hutchinson S, Caparrotta TM, Mellor J, Jeyam A, O'Reilly JE, Wild SH, Hatam S, Höhn A, Colombo M, Robertson C, Lone N, Murray J, Butterly E, Petrie J, Kennon B, McCrimmon R, Lindsay R, Pearson E, Sattar N, McKnight J, Philip S, Collier A, McMenamin J, Smith-Palmer A, Goldberg D, McKeigue PM, Colhoun HM; Public Health Scotland COVID-19 Health Protection Study Group; Scottish Diabetes Research Network Epidemiology Group. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021 Feb;9(2):82-93. doi: 10.1016/S2213-8587(20)30405-8. Epub 2020 Dec 23.</citation>
    <PMID>33357491</PMID>
  </reference>
  <reference>
    <citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775. Erratum in: JAMA. 2020 May 26;323(20):2098.</citation>
    <PMID>32320003</PMID>
  </reference>
  <reference>
    <citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394. Erratum in: JAMA. 2021 May 25;325(20):2120.</citation>
    <PMID>32250385</PMID>
  </reference>
  <reference>
    <citation>Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792. doi: 10.1016/S2213-8587(20)30238-2. Epub 2020 Jul 17. Review. Erratum in: Lancet Diabetes Endocrinol. 2020 Oct;8(10):e5. Lancet Diabetes Endocrinol. 2020 Nov;8(11):e6.</citation>
    <PMID>32687793</PMID>
  </reference>
  <reference>
    <citation>Quan J, Li TK, Pang H, Choi CH, Siu SC, Tang SY, Wat NMS, Woo J, Johnston JM, Leung GM. Diabetes incidence and prevalence in Hong Kong, China during 2006-2014. Diabet Med. 2017 Jul;34(7):902-908. doi: 10.1111/dme.13284. Epub 2016 Nov 29.</citation>
    <PMID>27859570</PMID>
  </reference>
  <reference>
    <citation>Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020 May 29;12(10):9959-9981. doi: 10.18632/aging.103344. Epub 2020 May 29.</citation>
    <PMID>32470948</PMID>
  </reference>
  <reference>
    <citation>Márquez EJ, Chung CH, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, Mellert DJ, Kuchel GA, Banchereau J, Ucar D. Sexual-dimorphism in human immune system aging. Nat Commun. 2020 Feb 6;11(1):751. doi: 10.1038/s41467-020-14396-9.</citation>
    <PMID>32029736</PMID>
  </reference>
  <reference>
    <citation>Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. Clin Rev Allergy Immunol. 2019 Jun;56(3):308-321. doi: 10.1007/s12016-017-8648-x. Review.</citation>
    <PMID>28963611</PMID>
  </reference>
  <reference>
    <citation>Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706. doi: 10.1136/gutjnl-2020-323020. Epub 2021 Jan 11.</citation>
    <PMID>33431578</PMID>
  </reference>
  <reference>
    <citation>Segal JP, Mak JWY, Mullish BH, Alexander JL, Ng SC, Marchesi JR. The gut microbiome: an under-recognised contributor to the COVID-19 pandemic? Therap Adv Gastroenterol. 2020 Nov 24;13:1756284820974914. doi: 10.1177/1756284820974914. eCollection 2020. Review.</citation>
    <PMID>33281941</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S, Chen J, Wang W, Chen B, Jiang L, Yu S, Lu J, Wang J, Xu M, Yuan Z, Zhang Q, Zhang X, Zhao G, Wang S, Chen S, Lu H. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020 Jul;583(7816):437-440. doi: 10.1038/s41586-020-2355-0. Epub 2020 May 20.</citation>
    <PMID>32434211</PMID>
  </reference>
  <reference>
    <citation>Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS, Ng SC. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 Sep;159(3):944-955.e8. doi: 10.1053/j.gastro.2020.05.048. Epub 2020 May 20.</citation>
    <PMID>32442562</PMID>
  </reference>
  <reference>
    <citation>Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK, Chen Z, Boon SS, Chan FK, Chan PK, Ng SC. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021 Feb;70(2):276-284. doi: 10.1136/gutjnl-2020-322294. Epub 2020 Jul 20.</citation>
    <PMID>32690600</PMID>
  </reference>
  <reference>
    <citation>Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121-41. doi: 10.1016/j.cell.2014.03.011. Review.</citation>
    <PMID>24679531</PMID>
  </reference>
  <reference>
    <citation>Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers. 2017 Oct 2;5(4):e1373208. doi: 10.1080/21688370.2017.1373208. Epub 2017 Sep 28. Review.</citation>
    <PMID>28956703</PMID>
  </reference>
  <reference>
    <citation>Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017 Apr;17(4):219-232. doi: 10.1038/nri.2017.7. Epub 2017 Mar 6. Review.</citation>
    <PMID>28260787</PMID>
  </reference>
  <reference>
    <citation>Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012 Oct 4;490(7418):55-60. doi: 10.1038/nature11450. Epub 2012 Sep 26.</citation>
    <PMID>23023125</PMID>
  </reference>
  <reference>
    <citation>Stenman LK, Waget A, Garret C, Briand F, Burcelin R, Sulpice T, Lahtinen S. Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. Diabetol Metab Syndr. 2015 Sep 12;7:75. doi: 10.1186/s13098-015-0075-7. eCollection 2015.</citation>
    <PMID>26366205</PMID>
  </reference>
  <reference>
    <citation>Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Lyon MR, Wood S. Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats. J Endocrinol. 2014 Feb 10;220(3):361-73. doi: 10.1530/JOE-13-0484. Print 2014 Mar.</citation>
    <PMID>24389593</PMID>
  </reference>
  <reference>
    <citation>Zheng J, Li H, Zhang X, Jiang M, Luo C, Lu Z, Xu Z, Shi J. Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic Effects of Metformin in Correlation with Modulating Gut Microbiota. J Agric Food Chem. 2018 Jun 13;66(23):5821-5831. doi: 10.1021/acs.jafc.8b00829. Epub 2018 Jun 5.</citation>
    <PMID>29701959</PMID>
  </reference>
  <reference>
    <citation>Landete JM, Gaya P, Rodríguez E, Langa S, Peirotén Á, Medina M, Arqués JL. Probiotic Bacteria for Healthier Aging: Immunomodulation and Metabolism of Phytoestrogens. Biomed Res Int. 2017;2017:5939818. doi: 10.1155/2017/5939818. Epub 2017 Oct 1. Review.</citation>
    <PMID>29109959</PMID>
  </reference>
  <reference>
    <citation>Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015 Mar;179(3):363-77. doi: 10.1111/cei.12474. Review.</citation>
    <PMID>25345825</PMID>
  </reference>
  <reference>
    <citation>Yan F, Polk DB. Probiotics and immune health. Curr Opin Gastroenterol. 2011 Oct;27(6):496-501. doi: 10.1097/MOG.0b013e32834baa4d. Review.</citation>
    <PMID>21897224</PMID>
  </reference>
  <reference>
    <citation>Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdigón G. Beneficial Effects of Probiotic Consumption on the Immune System. Ann Nutr Metab. 2019;74(2):115-124. doi: 10.1159/000496426. Epub 2019 Jan 23. Review.</citation>
    <PMID>30673668</PMID>
  </reference>
  <reference>
    <citation>de Jong SE, Olin A, Pulendran B. The Impact of the Microbiome on Immunity to Vaccination in Humans. Cell Host Microbe. 2020 Aug 12;28(2):169-179. doi: 10.1016/j.chom.2020.06.014. Review.</citation>
    <PMID>32791110</PMID>
  </reference>
  <reference>
    <citation>Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, Das J, Wang H, Guthmiller J, Zheng NY, Huang M, Uphadhyay AA, Gardinassi L, Petitdemange C, McCullough MP, Johnson SJ, Gill K, Cervasi B, Zou J, Bretin A, Hahn M, Gewirtz AT, Bosinger SE, Wilson PC, Li S, Alter G, Khurana S, Golding H, Pulendran B. Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell. 2019 Sep 5;178(6):1313-1328.e13. doi: 10.1016/j.cell.2019.08.010.</citation>
    <PMID>31491384</PMID>
  </reference>
  <reference>
    <citation>Davidson LE, Fiorino AM, Snydman DR, Hibberd PL. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr. 2011 Apr;65(4):501-7. doi: 10.1038/ejcn.2010.289. Epub 2011 Feb 2.</citation>
    <PMID>21285968</PMID>
  </reference>
  <reference>
    <citation>Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ. 2021 Jan 15;372:n149. doi: 10.1136/bmj.n149.</citation>
    <PMID>33451975</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Mak Wing Yan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

